New evidence
A meta-analysis of 27 trials linked 3,000 mg/day taurine to lower HbA1c — but every participant had long COVID, so the result may not apply to healthy people.
This is the first moderately strong evidence that taurine might improve blood sugar control, but it comes entirely from people recovering from COVID-19, and the underlying studies disagreed on how much it helped — so treat it as an early signal, not a settled fact.
Researchers pooled 27 clinical trials and found that people with long COVID who took 3,000 mg of taurine per day had lower hemoglobin A1c (a measure of average blood sugar over the past 2–3 months), along with improvements in fasting glucose, insulin, cholesterol, and inflammation markers. However, the evidence is rated as moderate, with mixed results across individual studies, and the findings may not generalize beyond the specific clinical population studied.
Where this fits in the evidence
Pillser has synthesized 3 studies on Taurine for Reduced Hemoglobin A1c — overall evidence strength: Moderate.
Across 3 studies (including two meta-analyses), 2 reported beneficial effects on reducing hemoglobin A1c, with effect sizes ranging from small to moderate; one randomized controlled trial protocol reported a neutral finding (not yet completed). The most-studied dose was 3 g/day, and the median study duration was 180 days. Evidence primarily comes from meta-analyses of clinical trials in populations with metabolic dysfunction or overweight/obesity.
The study
- Meta-Analysis
- n = 308
- 2026-03-10
- BMC infectious diseases
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.